A carregar...
In Vitro Evaluation of Guanidine Analogs as Sigma Receptor Ligands for Potential Anti-Stroke Therapeutics
Currently, the only Food and Drug Administration–approved treatment of acute stroke is recombinant tissue plasminogen activator, which must be administered within 6 hours after stroke onset. The pan-selective σ-receptor agonist N,N′-di-o-tolyl-guanidine (o-DTG) has been shown to reduce infarct volum...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3533416/ https://ncbi.nlm.nih.gov/pubmed/23065135 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.112.199513 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|